Abstract

Fear of cancer recurrence (FCR) is a common and persistent concern among breast cancer survivors. Little is known about factors associated with FCR in women with ductal carcinoma in situ (DCIS) or early invasive breast cancer (EIBC). Women with first primary DCIS, or stages I-IIA breast cancer were prospectively enrolled in a quality-oflife study and completed interviews at 4-6 weeks, 6 months, and 2 years after definitive surgical treatment. In three stepwise multivariable linear regression models, including both time-independent and time-varying variables measured at each respective interview, we identified independent correlatesof mean FCR scores (range 1-6) using four items from the Concern About Recurrence Scale (CARS) at 2-year follow-up. Of 506 disease-free patients at 2-year follow-up (mean [SD] age, 58 [10] years; 81% White; 34% DCIS), the average FCR score of 2.0 was low. However, 145 (29%) reported moderate-to-high levels of FCR (scores 3.0-6.0). All three models showed that younger age, stage IIA breast cancer (vs. DCIS), lower social support, and elevated anxiety were consistently associated with higher FCR at 2-year follow-up (each P<0.05; final models R2 = 0.25-0.32). DCIS patients reported lower FCR than stage IIA patients (each P ≥ 0.01) but had similar FCR as stage I patients. Although mean FCR was low, 29% of DCIS and EIBC survivors reported moderate-to-high levels of FCR at 2-year follow-up. Management of anxiety, provision of social support, and patient education may help reduce FCR among DCIS and EIBC survivors, especially among younger survivors.

Original languageEnglish
Pages (from-to)165-173
Number of pages9
JournalBreast Cancer Research and Treatment
Volume130
Issue number1
DOIs
StatePublished - Nov 2011

Keywords

  • Anxiety
  • Breast cancer
  • Cancer risk perception
  • Ductal carcinoma in situ
  • Fear of cancer recurrence
  • Social support

Fingerprint

Dive into the research topics of 'Correlates of fear of cancer recurrence in women with ductal carcinoma in situ and early invasive breast cancer'. Together they form a unique fingerprint.

Cite this